Mark Day, PhD

I am also a Senior Director in Corporate Development at Alexion Pharmaceuticals focused on ultra rare diseases. Prior to this, I led CNS Business Development at BMS and I was the responsible for the identification & evaluation of the iPierian opportunity (extracellular Tau for PSP). The acquisition was announced on April 31st 2014. I was also responsible for identifying and working with OliPass (a private Korean Biotech focused on PNA-based therapeutics), leading to the announcement of a Worldwide Discovery Alliance with Bristol-Myers Squibb (Oct 2014). My previous appointments included the Head of Translational Imaging and Biochemical Biomarkers (Abbott Labs), Snr Director and Head of Cognitive Neurosciences (Psychogenics), Translational Neuroscience (Wyeth Labs), Principal Investigator (GSK) and I was a Senior Research Fellow (University of Edinburgh) with Richard Morris. I have published over 50 peer-reviewed articles.